Waters Corporation (0LTI.L)
USD 330.95
(5.07%)
USD 330.95
(5.07%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 642.23 Million USD | -9.26% |
| 2022 | 707.75 Million USD | 2.15% |
| 2021 | 692.84 Million USD | 32.84% |
| 2020 | 521.57 Million USD | -11.93% |
| 2019 | 592.19 Million USD | -0.27% |
| 2018 | 593.79 Million USD | 2823.51% |
| 2017 | 20.31 Million USD | -96.11% |
| 2016 | 521.5 Million USD | 11.18% |
| 2015 | 469.05 Million USD | 8.67% |
| 2014 | 431.62 Million USD | -4.09% |
| 2013 | 450 Million USD | -2.48% |
| 2012 | 461.44 Million USD | 6.58% |
| 2011 | 432.96 Million USD | 13.41% |
| 2010 | 381.76 Million USD | 18.08% |
| 2009 | 323.31 Million USD | 0.26% |
| 2008 | 322.47 Million USD | 20.3% |
| 2007 | 268.07 Million USD | 20.64% |
| 2006 | 222.2 Million USD | 10.01% |
| 2005 | 201.97 Million USD | -9.85% |
| 2004 | 224.05 Million USD | 31.11% |
| 2003 | 170.89 Million USD | 15.69% |
| 2002 | 147.71 Million USD | 28.96% |
| 2001 | 114.54 Million USD | -21.19% |
| 2000 | 145.34 Million USD | 18.84% |
| 1999 | 122.3 Million USD | 64.38% |
| 1998 | 74.4 Million USD | 996.39% |
| 1997 | -8.3 Million USD | -245.83% |
| 1996 | -2.4 Million USD | -220.0% |
| 1995 | 2 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 102.19 Million USD | -52.73% |
| 2024 Q3 | 161.5 Million USD | 13.15% |
| 2024 Q2 | 142.73 Million USD | 39.67% |
| 2023 Q2 | 150.55 Million USD | 6.83% |
| 2023 Q1 | 140.92 Million USD | -37.94% |
| 2023 Q4 | 216.2 Million USD | 60.69% |
| 2023 FY | 642.23 Million USD | -9.26% |
| 2023 Q3 | 134.55 Million USD | -10.63% |
| 2022 Q3 | 155.99 Million USD | -5.38% |
| 2022 Q4 | 227.06 Million USD | 45.55% |
| 2022 FY | 707.75 Million USD | 2.15% |
| 2022 Q1 | 159.83 Million USD | -26.09% |
| 2022 Q2 | 164.86 Million USD | 3.15% |
| 2021 Q4 | 216.23 Million USD | 34.16% |
| 2021 FY | 692.84 Million USD | 32.84% |
| 2021 Q2 | 167.29 Million USD | 12.94% |
| 2021 Q3 | 161.18 Million USD | -3.65% |
| 2021 Q1 | 148.12 Million USD | -32.15% |
| 2020 Q3 | 126.76 Million USD | 3.12% |
| 2020 Q2 | 122.92 Million USD | 129.51% |
| 2020 FY | 521.57 Million USD | -11.93% |
| 2020 Q1 | 53.56 Million USD | -73.31% |
| 2020 Q4 | 218.31 Million USD | 72.21% |
| 2019 Q3 | 138.13 Million USD | -4.35% |
| 2019 FY | 592.19 Million USD | -0.27% |
| 2019 Q1 | 108.98 Million USD | -41.14% |
| 2019 Q2 | 144.41 Million USD | 32.5% |
| 2019 Q4 | 200.66 Million USD | 45.27% |
| 2018 Q4 | 185.15 Million USD | 31.3% |
| 2018 FY | 593.79 Million USD | 2823.51% |
| 2018 Q2 | 155.67 Million USD | 39.06% |
| 2018 Q1 | 111.95 Million USD | 131.7% |
| 2018 Q3 | 141.01 Million USD | -9.42% |
| 2017 Q3 | 136.1 Million USD | 3.25% |
| 2017 FY | 20.31 Million USD | -96.11% |
| 2017 Q4 | -353.17 Million USD | -359.49% |
| 2017 Q1 | 105.55 Million USD | -39.47% |
| 2017 Q2 | 131.82 Million USD | 24.88% |
| 2016 Q4 | 174.37 Million USD | 39.66% |
| 2016 Q2 | 128.21 Million USD | 36.33% |
| 2016 Q1 | 94.05 Million USD | -37.74% |
| 2016 FY | 521.5 Million USD | 11.18% |
| 2016 Q3 | 124.85 Million USD | -2.62% |
| 2015 Q1 | 96.06 Million USD | -36.51% |
| 2015 Q3 | 116.28 Million USD | 10.06% |
| 2015 Q4 | 151.05 Million USD | 29.9% |
| 2015 FY | 469.05 Million USD | 8.67% |
| 2015 Q2 | 105.65 Million USD | 9.99% |
| 2014 Q1 | 70.3 Million USD | -50.35% |
| 2014 Q2 | 96.52 Million USD | 37.31% |
| 2014 Q3 | 113.49 Million USD | 17.58% |
| 2014 Q4 | 151.29 Million USD | 33.3% |
| 2014 FY | 431.62 Million USD | -4.09% |
| 2013 FY | 450 Million USD | -2.48% |
| 2013 Q4 | 141.58 Million USD | 44.4% |
| 2013 Q1 | 121.05 Million USD | -31.19% |
| 2013 Q3 | 98.04 Million USD | 9.78% |
| 2013 Q2 | 89.31 Million USD | -26.22% |
| 2012 Q1 | 88.66 Million USD | -35.35% |
| 2012 Q2 | 97.72 Million USD | 10.22% |
| 2012 Q3 | 99.1 Million USD | 1.42% |
| 2012 Q4 | 175.94 Million USD | 77.53% |
| 2012 FY | 461.44 Million USD | 6.58% |
| 2011 Q1 | 94.48 Million USD | -25.37% |
| 2011 FY | 432.96 Million USD | 13.41% |
| 2011 Q3 | 101.25 Million USD | 1.18% |
| 2011 Q4 | 137.14 Million USD | 35.44% |
| 2011 Q2 | 100.07 Million USD | 5.91% |
| 2010 Q2 | 84.92 Million USD | 12.45% |
| 2010 FY | 381.76 Million USD | 18.08% |
| 2010 Q4 | 126.6 Million USD | 33.66% |
| 2010 Q3 | 94.71 Million USD | 11.54% |
| 2010 Q1 | 75.51 Million USD | -27.47% |
| 2009 Q4 | 104.12 Million USD | 37.12% |
| 2009 FY | 323.31 Million USD | 0.26% |
| 2009 Q2 | 69.9 Million USD | -4.69% |
| 2009 Q3 | 75.93 Million USD | 8.62% |
| 2009 Q1 | 73.34 Million USD | -26.18% |
| 2008 FY | 322.47 Million USD | 20.3% |
| 2008 Q4 | 99.35 Million USD | 38.95% |
| 2008 Q3 | 71.5 Million USD | -14.01% |
| 2008 Q2 | 83.14 Million USD | 21.43% |
| 2008 Q1 | 68.47 Million USD | -30.79% |
| 2007 Q1 | 55.93 Million USD | -29.98% |
| 2007 Q3 | 53.28 Million USD | -11.06% |
| 2007 Q2 | 59.9 Million USD | 7.1% |
| 2007 Q4 | 98.94 Million USD | 85.69% |
| 2007 FY | 268.07 Million USD | 20.64% |
| 2006 FY | 222.2 Million USD | 10.01% |
| 2006 Q2 | 47.78 Million USD | 8.21% |
| 2006 Q1 | 44.15 Million USD | -41.59% |
| 2006 Q3 | 50.37 Million USD | 5.43% |
| 2006 Q4 | 79.88 Million USD | 58.59% |
| 2005 FY | 201.97 Million USD | -9.85% |
| 2005 Q2 | 54.06 Million USD | 16.03% |
| 2005 Q3 | 25.71 Million USD | -52.43% |
| 2005 Q4 | 75.59 Million USD | 193.96% |
| 2005 Q1 | 46.59 Million USD | -34.85% |
| 2004 FY | 224.05 Million USD | 31.11% |
| 2004 Q1 | 40.84 Million USD | -30.06% |
| 2004 Q2 | 59.75 Million USD | 46.29% |
| 2004 Q3 | 51.94 Million USD | -13.07% |
| 2004 Q4 | 71.51 Million USD | 37.69% |
| 2003 Q4 | 58.4 Million USD | 60.38% |
| 2003 FY | 170.89 Million USD | 15.69% |
| 2003 Q3 | 36.41 Million USD | -13.5% |
| 2003 Q1 | 33.97 Million USD | -15.57% |
| 2003 Q2 | 42.09 Million USD | 23.9% |
| 2002 Q4 | 40.24 Million USD | 3.13% |
| 2002 Q3 | 39.02 Million USD | 2.96% |
| 2002 Q2 | 37.9 Million USD | 7.55% |
| 2002 Q1 | 35.24 Million USD | 2588.7% |
| 2002 FY | 147.71 Million USD | 28.96% |
| 2001 Q1 | 38.4 Million USD | -2.85% |
| 2001 Q2 | 39.31 Million USD | 2.38% |
| 2001 Q4 | -1.41 Million USD | -103.7% |
| 2001 Q3 | 38.24 Million USD | -2.71% |
| 2001 FY | 114.54 Million USD | -21.19% |
| 2000 Q4 | 39.52 Million USD | 3.36% |
| 2000 Q1 | 30.31 Million USD | -26.77% |
| 2000 Q2 | 37.25 Million USD | 22.88% |
| 2000 Q3 | 38.24 Million USD | 2.65% |
| 2000 FY | 145.34 Million USD | 18.84% |
| 1999 Q1 | 23 Million USD | -28.35% |
| 1999 FY | 122.3 Million USD | 64.38% |
| 1999 Q4 | 41.4 Million USD | 42.76% |
| 1999 Q3 | 29 Million USD | 0.35% |
| 1999 Q2 | 28.9 Million USD | 25.65% |
| 1998 FY | 74.4 Million USD | 996.39% |
| 1998 Q4 | 32.1 Million USD | 45.91% |
| 1998 Q3 | 22 Million USD | 9.45% |
| 1998 Q2 | 20.1 Million USD | 9950.0% |
| 1998 Q1 | 200 Thousand USD | -96.49% |
| 1997 Q3 | -41.1 Million USD | -377.7% |
| 1997 Q4 | 5.7 Million USD | 113.87% |
| 1997 Q1 | 12.3 Million USD | -19.08% |
| 1997 FY | -8.3 Million USD | -245.83% |
| 1997 Q2 | 14.8 Million USD | 20.33% |
| 1996 FY | -2.4 Million USD | -220.0% |
| 1996 Q3 | 6.4 Million USD | 119.88% |
| 1996 Q2 | -32.2 Million USD | -492.68% |
| 1996 Q1 | 8.2 Million USD | 176.64% |
| 1996 Q4 | 15.2 Million USD | 137.5% |
| 1995 Q3 | 9.3 Million USD | 116.28% |
| 1995 Q1 | -900 Thousand USD | 0.0% |
| 1995 FY | 2 Million USD | 0.0% |
| 1995 Q4 | -10.7 Million USD | -215.05% |
| 1995 Q2 | 4.3 Million USD | 577.78% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 89.287% |
| Dynavax Technologies Corporation | -6.38 Million USD | 10152.183% |
| Illumina, Inc. | -1.16 Billion USD | 155.317% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 52.707% |
| Biogen Inc. | 1.16 Billion USD | 44.687% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 244.635% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 18.579% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 219.825% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -48701.976% |
| Perrigo Company plc | -12.7 Million USD | 5156.961% |
| uniQure N.V. | -308.47 Million USD | 308.194% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 282.407% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 523.682% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 332.587% |
| bluebird bio, Inc. | -211.91 Million USD | 403.065% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 641.91% |
| Imunon, Inc. | -19.51 Million USD | 3390.98% |
| Myriad Genetics, Inc. | -112 Million USD | 673.423% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | -157.202% |
| Nektar Therapeutics | -276.05 Million USD | 332.646% |
| Editas Medicine, Inc. | -153.21 Million USD | 519.161% |
| Verastem, Inc. | -87.36 Million USD | 835.099% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 107.437% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 1539.879% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 680.897% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 1711.224% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -283.092% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 349.091% |
| Evolus, Inc. | -61.68 Million USD | 1141.151% |
| Adicet Bio, Inc. | -142.65 Million USD | 550.191% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 825.844% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 83.756% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 406.925% |
| FibroGen, Inc. | -284.23 Million USD | 325.954% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 48.207% |
| OPKO Health, Inc. | -188.86 Million USD | 440.053% |
| Homology Medicines, Inc. | -53.74 Million USD | 1295.01% |
| Geron Corporation | -184.12 Million USD | 448.799% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 245.882% |
| Exelixis, Inc. | 207.76 Million USD | -209.116% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 847.697% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 1451.929% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 233.467% |
| Zoetis Inc. | 2.34 Billion USD | 72.601% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 368.45% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 1285.196% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 82.257% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 1621.918% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 275.337% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -505.082% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | -128.071% |
| Blueprint Medicines Corporation | -506.98 Million USD | 226.677% |
| Insmed Incorporated | -749.56 Million USD | 185.681% |
| TG Therapeutics, Inc. | 12.67 Million USD | -4968.134% |
| Incyte Corporation | 597.59 Million USD | -7.469% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 184.449% |